ProPharma Group, a portfolio company of Linden Capital Partners, has announced the acquisition of Southwood Research.
Based in Buckinghamshire, Southwood Research is a provider of pre-approval regulatory science services to the pharmaceutical and biotech industries.
This acquisition extends ProPharma Group’s highly specialised scientific regulatory affairs capabilities throughout the EU marketplace, while bolstering its regulatory affairs service portfolio from pre-clinical/pre-approval through post-approval.
ProPharma Group now has more than 1100 employees across the United States, Canada, Europe, Japan, and Australia.
Dawn Sherman, ProPharma Group’s CEO, said: “ProPharma Group’s robust regulatory capabilities, bolstered by the recent additions of The Weinberg Group in the United States and now Southwood Research in the UK, represent a truly unique end-to-end global regulatory practice.”
Michael Farah, Chairman of ProPharma and Partner at Linden Capital Partners, said: “We are excited to support the entire ProPharma Group organisation as they expand their global presence and enhance their existing portfolio of services.”
Colin Wheeler, Southwood Research’s Managing Director, said: “We are thrilled about our future as a part of ProPharma Group. The combination expands our global reach, as well as our ability to provide end-to-end services for our clients within regulatory affairs.”